This research investigates whether weight loss from the GLP-1 drug semaglutide includes loss of muscle mass. Using an obesity mouse model and direct muscle measurements, the study found significant muscle loss in females but not males. The findings highlight important sex differences and the need to evaluate body composition, not just weight loss.